Clementia Pharmaceuticals

Biotech & Life Sciences · Montreal, Canada · Founded 2012 · IPO 2017

Clementia Pharmaceuticals, a subsidiary of Ipsen, operates as a global biopharmaceutical company with a strong focus on developing innovative treatments for oncology, neuroscience, and rare diseases. The company aims to launch at least one new drug or meaningful indication each year, demonstrating a commitment to continuous innovation and patient care. Clementia serves a diverse range of clients, including healthcare providers, patients, and research institutions, primarily in the pharmaceutical and biotechnology markets. The business model revolves around research and development, clinical trials, and commercialization of new therapies. Revenue is generated through the sale of these therapies, partnerships, and collaborations with other pharmaceutical companies. The company leverages its biotech mindset and robust development and commercialization teams to maintain a competitive edge in the market. Keywords: biopharmaceutical, oncology, neuroscience, rare diseases, innovation, clinical trials, commercialization, patient care, research, development.

Valuation $1–2.5B

Headcount <100

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier

Investors

6 investors on Clementia Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

BDC Capital

OrbiMed

Series B+ 4 investors entered at this stage

Janus Capital Group

NEA

Rock Springs Capital

Fonds de solidarité FTQ

Global footprint

Where Clementia Pharmaceuticals has talent and traffic

Workforce by country

2 countries with
team presence

🇨🇦 Canada50%

🇮🇳 India50%

2 countries shown

Talent graph

The shape of Clementia Pharmaceuticals's talent

Dealroom maps Clementia Pharmaceuticals's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

11 standout operatorsDealroom-flagged across the org

13 AI specialistsincl. 3 core researchers

DimensionScore

AI Talentlive

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Clementia Pharmaceuticals's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$9M patent portfolio · 3 active families

Estimated portfolio value

$9M

0.71% of market cap · 764.9× smaller than top peer Janssen Vaccines ($7.1B)

3 active patent families

Where Clementia Pharmaceuticals innovates Antisense Oligonucleotide TherapyDosing regimenEndocrinologyGenomic cloneImatinib

Where Clementia Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Clementia Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Clementia Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Clementia Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Clementia Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles